Sermorelin vs CJC-1295

Side-by-side comparison of Sermorelin, CJC-1295 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Sermorelin Sermorelin Acetate (GHRH 1-29) Growth Hormone CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone
Basics
Molecular type GHRH AnalogueGHRH Analogue
Amino acids 2929
Molecular weight 3,357.9 Da3,368.9 Da
Half-life ~10–20 min30 min (without DAC) / 7–8 days (with DAC)
Route(s) Subcutaneous, IV (diagnostic only)Subcutaneous, Intramuscular
Mechanism & Research
Primary mechanism Sermorelin binds GHRH receptors in the anterior pituitary with similar affinity to native GHRH and stimulates GH synthesis and secretion. Its mechanism is essentially identical to endogenous GHRH — it is distinguished pr… CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi…
Research status Research Compound Research Compound
Evidence summary Sermorelin has more human clinical data than any other GHRH analogue due to its period of FDA approval. Adult studies have examined it for age-related GH decline, body composition, and sleep quality. Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs.
Protocol & Dosing
Typical dose 200–500 mcg100–200 mcg (without DAC); 2mg every 2 weeks (with DAC)
Frequency Once daily at bedtime2–3x daily (without DAC); biweekly (with DAC)
Duration 3–6 months8–16 weeks
Timing Bedtime (maximises nocturnal GH pulse)Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly.
Safety
Common side effects
  • Injection site pain/redness
  • Flushing
  • Headache
  • Dizziness (rare)
  • Water retention
  • Mild headache
  • Flushing (post-injection)
  • Tingling
Contraindications
  • Active malignancy
  • Hypothyroidism (treat first)
  • Pregnancy
  • Active malignancy
  • Uncontrolled hypothyroidism
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides CJC-1295, Ipamorelin, Tesamorelin Ipamorelin, Sermorelin, GHRP-2, Tesamorelin
Full profile Read full Sermorelin profile → Read full CJC-1295 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.